Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer.

Front Pharmacol · 2022 · PMC9531711 · PMID 36204232

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

We observed that the top-order eleven leading compounds/drugs (YM201636, masitinib, SB590885, GSK1070916, GSK2126458, ZSTK474, dasatinib, TG101348, dabrafenib, methotrexate, and trametinib) produced highly significant binding affinity scores (BAS) < −7 with all target proteins.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.